- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04877080
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
February 8, 2023 updated by: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Exploratory Study to Evaluate Efficacy and Safety of Fast Dual CAR-T Injection in CD19+ Refractory or Relapsed B Cell Non-Hodgkinlymphoma
This is a single arm, open-label, single-center prospective study to determine the safety and efficacy of Fast Dual CAR-T cells in patients diagnosed with CD19+ refractory/relapsed B cell non-Hodgkinlymphoma (R/R B-NHL).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The main aim of the study is to determine the safety and efficacy of Fast Dual CAR-T in R/R B-NHL.
Fast Dual CAR-T is an autologous dual chimeric antigen receptor T-cell (CAR-T) therapy that targets CD19 and B-cell maturation antigen (BCMA).
The study will include 15 subjects to receive Fast Dual CAR-T single infusion.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Histologically confirmed: Diffuse Large B Cell Lymphoma (DLBCL), Transformation Follicular Lymphoma (TFL), Primary Mediastinal Large B Cell Lymphoma (PMBCL) and Mantle Cell Lymphoma (MCL), High-Grade B Cell Lymphoma (HGBL);
- Refractory B-NHL: PD as the best response to normative first-line therapy (intolerance of first-line therapy is not included in this study) or SD as the best response to at least 4 courses of first-line therapy with duration no longer than 6 month from last therapy; or PD as the best response to the last therapy of second-line therapy and above,or SD as the best response to at least 2 courses of second-line therapy with duration no longer than 6 month from last therapy, or:
- Relapsed B-NHL: Histopathology confirmed relapse after standard systemic and second-line therapy achieved CR, or histopathologically confirmed relapse within 1 year after autologous hematopoietic stem cell transplantation (Not limited by previous therapy);
- Prior therapy must include anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and an anthracycline;
- For individual with TFL, must have chemotherapy and the conform the above definition of relapse or refractory after transformation;
- According to the 2014 Lugano therapy response standard, there should be at least one measurable tumor focus: the longest diameter of nodular lesions> 1.5 cm, and the longest diameter of extranodal lesions> 1.0 cm;
- CD19 positive expression in tumor tissue biopsy;
- Prior to apheresis, approved anti-B-NHL therapys such as systemic chemotherapy, systemic radiotherapy and immunotherapy have been completed for at least 2 weeks;
- Eastern cooperative oncology group (ECOG) performance status of 0 to 1;
- Life expectancy ≥12 weeks;
- Absolute neutrophil count (ANC)≥ 1×10^9/L;
- Platelet count≥50×10^9/L;
- Absolute lymphocyte count (ALC)≥1×10^8/L;
Adequate organ function defined as:
- Serum ALT/AST ≤2.5 ULN;
- Creatinine clearance (as estimated by Cockcroft Gault) ≥60 mL/min;
- PT and APTT≤1.5 ULN
- Total bilirubin ≤1.5 ULN;
- Cardiac ejection fraction ≥50%, no pericardial effusion, no clinically significant ECG findings;
- Baseline oxygen saturation >92% on room air;
- Sufficient venous access for leukapheresis collection, and no other contraindications to leukapheresis;
- Female of childbearing age must agree to take effective contraceptive measures at least 1 year after infusion; Male with fertile partners must agree to use effective barrier contraceptive methods at least 1 year after infusion;
- Understand and voluntarily sign the informed consent form.
Exclusion Criteria:
- Diagnosis of other malignancy (except for cured non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, ductal carcinoma in situ, or other malignancies that have completely responsed for more than 5 years);
- Severe mental disorders;
- History of hereditary diseases, including but not limited to: Fanconi anemia, Shut-Dai syndrome, Costman syndrome or any other known bone marrow failure syndrome;
- History of allogeneic stem cell transplantation;
- Grade III-IV heart failure or myocardial infarction, angioplasty or stent placement, unstableangina pectoris, or other clinically prominent heart disease within one year before enrollment.
- Have any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, indwelling catheter, bile drainage tube or pleura / peritoneum / pericardial catheter), the use of dedicated central venous catheter is allowed;
- Subjects with CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases;
- History or presence of CNS disorder, including but not limited to: seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement;
- Positive for any of the following etiological tests: HIV, HBV, HCV, TPPA;
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled;
- Allergic subjects or subjects with severe allergic reactions to cyclophosphamide or fludarabine;
- History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years;
- History or diagnosis of pulmonary fibrosis;
- Have received gene therapy or any other CAR-T treatment;
- Have received any other drugs targeting CD19;
- Subjects who received other clinical trial therapy within 4 weeks before participating in this trial, or the informed consent form was signed within the 5 half-life of the last administration in the other clinical trial (take longer time as standard);
- Poor adherence due to physical, family, social, geographic, and other factors, who cannot follow the research plan and follow-up plan;
- Subjects with comorbidities that require systemic corticosteroid therapy (≥5 mg/day of prednisone or an equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months after study therapy according to the discretion of investigator;
- Lactating women who are reluctant to stop breastfeeding;
- Any other conditions defined by researcher that is inappropriate for the subject to be enrolled.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fast Dual CAR-T treatment
CD19+ R/R B-NHL patients be treated with a single dose of Fast Dual CAR-T cells.
Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
|
Fast Dual CAR-T injection is a autologous dual CAR-T targeted CD19 and BCMA.
A single infusion of CART cells will be administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AE after Fast Dual CAR-T infusion
Time Frame: up to 24 weeks after Fast Dual CAR-T infusion
|
Incidence of adverse events after Fast Dual CAR-T infusion
|
up to 24 weeks after Fast Dual CAR-T infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR rate
Time Frame: 12 weeks, 24 weeks after Fast Dual CAR-T infusion
|
Overall response rate (ORR=CR+CRi) after Fast Dual CAR-T infusion
|
12 weeks, 24 weeks after Fast Dual CAR-T infusion
|
PFS
Time Frame: 12 weeks, 24 weeks after Fast Dual CAR-T infusion
|
Progression free survival (PFS) after Fast Dual CAR-T infusion
|
12 weeks, 24 weeks after Fast Dual CAR-T infusion
|
OS
Time Frame: 12 weeks, 24 weeks after Fast Dual CAR-T infusion
|
overall survival (OS) after Fast Dual CAR-T infusion
|
12 weeks, 24 weeks after Fast Dual CAR-T infusion
|
Change of CAR Copies
Time Frame: Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after Fast Dual CAR-T infusion
|
CAR Copies measured by qPCR after Fast Dual CAR-T infusion
|
Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after Fast Dual CAR-T infusion
|
Change of CAR-T cell counts
Time Frame: Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after Fast Dual CAR-T infusion
|
CAR-T cell counts measured by Flow cytometry after Fast Dual CAR-T infusion
|
Days 4, 7, 10, 14 and weeks 4, 8, 12, 18, 24 after Fast Dual CAR-T infusion
|
Changes in the concentration of cytokine IL-1, IL-2, IL-6, IL-10, TNF-α and IFN-γ.
Time Frame: Days 4, 7, 10, 14 and 28 after Fast Dual CAR-T infusion
|
Cytokines in serum measured by ELISA after Fast Dual CAR-T infusion
|
Days 4, 7, 10, 14 and 28 after Fast Dual CAR-T infusion
|
Change of RCL in blood
Time Frame: Weeks 4, 12, 24 after Fast Dual CAR-T infusion
|
Replication competent lentivirus (RCL) in blood after Fast Dual CAR-T infusion
|
Weeks 4, 12, 24 after Fast Dual CAR-T infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
May 5, 2021
Primary Completion (ANTICIPATED)
June 30, 2023
Study Completion (ANTICIPATED)
December 31, 2023
Study Registration Dates
First Submitted
April 13, 2021
First Submitted That Met QC Criteria
May 5, 2021
First Posted (ACTUAL)
May 7, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2023
Last Update Submitted That Met QC Criteria
February 8, 2023
Last Verified
February 1, 2023
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Lymphoma
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
Clinical Trials on Fast Dual CAR-T Injection
-
He HuangYake Biotechnology Ltd.RecruitingRelapsed and Refractory | Lymphoid Hematological MalignanciesChina
-
920th Hospital of Joint Logistics Support Force...Gracell Biotechnology Shanghai Co., Ltd.RecruitingAcute Myeloid LeukemiaChina
-
Shenzhen University General HospitalUnknownRefractory B Acute Lymphoblastic Leukemia | Relapse | B ALL | Dual-target CAR-T CellsChina
-
Xijing HospitalGracell Biotechnology Ltd.Unknown
-
Shanghai Cell Therapy Group Co.,LtdRecruiting
-
YuLiUnknownLymphoma, B-Cell | Refractory Lymphoma | Relapse/Recurrence | Dual-target CAR-T CellsChina
-
Yan'an Affiliated Hospital of Kunming Medical UniversityKAEDIUnknownB Cell Lymphoma | B-cell Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina